AI Enhances Meibomian Gland Detection - Takeaways - MDSpire

AI Enhances Meibomian Gland Detection

AI-powered spectral imaging shown by proof-of-concept study to advance MGD diagnosis

  • June 16, 2026

  • 3 min

Share

  • 1

    A new hyperspectral imaging platform using AI shows over 96% accuracy in diagnosing meibomian gland dysfunction (MGD), surpassing traditional methods.

  • 2

    The study utilized spectral convolutional neural network (SCNN) technology to analyze meibomian gland tissue from 11 patients, revealing distinct spectral signatures.

  • 3

    Hyperspectral imaging captures biochemical changes in tissues, providing more objective diagnostics compared to subjective clinical assessments currently used.

  • 4

    The SCNN chip enables rapid spectral acquisition and in-sensor computing, making it suitable for real-time clinical applications in ophthalmology.

  • 5

    Future research is needed to validate these findings with larger cohorts and in vivo imaging, as current limitations include small sample size and ex vivo analysis.

Original Source(s)

AI Enhances Meibomian Gland Detection

  • June 16, 2026

Related Content

Biocompatibility and Contact Lens Wear

In this feature, Alex Hui, OD, PhD, looks at the research and determines that contact lenses could be considered one of the most successful examples of biocompatible devices used. He further examines contact lens dropout and how to achieve contact lens wear success.

Dry Eye After Cataract Surgery

Scientific Reports study compares dry eye effects of phacoemulsification and MSICS

  • February 16, 2026

  • 3 min
Demodex: Another Means of Preventing Contact Lens Dropout?

Attendees of the lecture, “Focus on the Lids for OSD Success,” which was provided by Melissa Barnett, OD, learned, in part, about another focus for deterring contact lens dropout: identifying Demodex.